Outcome
    Moderate Evidence

    Omega-3 Fatty Acids for Pregnancy Support

    DHA supports fetal neurodevelopment and modestly reduces preterm birth risk.

    Overview

    Omega-3 in pregnancy is backed by one of the largest evidence bases in supplement science. A Cochrane review covering nearly 20,000 women found omega-3 supplementation reduced preterm birth before 37 weeks and early preterm birth, with a small increase in prolonged gestation.
    Preterm birth is a hard clinical outcome with major consequences, so a reduction of that kind carries far more weight than the biomarker findings typical of this field. The reduction in early preterm birth matters most, because those are the deliveries with the highest risk. The small increase in prolonged gestation is the honest trade-off and the reason obstetric monitoring still applies. It is not a reason to avoid supplementation, but it is why this belongs in a conversation with your maternity team rather than a private decision at the pharmacy shelf.

    Verdict

    Likely effective

    Cochrane review of nearly 20,000 women shows reduced preterm and early preterm birth with omega-3, alongside a small increase in prolonged gestation.

    How It Works

    The onset of labour is driven partly by prostaglandins derived from arachidonic acid, particularly PGE2 and PGF2 alpha, which soften the cervix and stimulate uterine contraction.
    EPA and DHA compete with arachidonic acid for the same enzymes, reducing production of these labour-initiating prostaglandins. That directly explains both findings at once: fewer preterm deliveries, and a small shift toward longer gestation in some pregnancies. DHA has a second, separate role. It accumulates rapidly in the fetal brain and retina during the third trimester, drawn from maternal stores, which is why maternal intake matters most in later pregnancy.
    Labour mechanism
    Reduced arachidonic acid-derived prostaglandins PGE2 and PGF2 alpha
    Consequence
    Fewer preterm births, slight shift to longer gestation
    Fetal role
    DHA accumulation in brain and retina in the third trimester
    Source of fetal DHA
    Maternal stores and intake
    Key window
    Second and third trimester

    Dosing & Protocol

    Pregnancy trials generally use 500 to 1000 mg of DHA daily, often within a combined EPA and DHA product, started in the second trimester. Purity matters more here than anywhere else, because of mercury and contaminant concerns.
    ContextDoseFormTiming
    Common trial dose500-1000 mg DHA dailyPurified fish oil or algal oilFrom the second trimester
    Combined product1 g combined EPA+DHA, DHA-weightedPrenatal-specific omega-3Daily with a meal
    Vegan option500-1000 mg DHAAlgal oilDaily with food
    Assessment windowThrough pregnancy and lactationAny purified formDaily
    1. 1

      Raise it with your maternity team first· Before starting

      Supplementation in pregnancy should be documented and monitored, particularly given the prolonged gestation finding.

    2. 2

      Choose a purified, tested product· Before buying

      Third-party testing for mercury, PCBs and dioxins is essential in pregnancy.

    3. 3

      Avoid cod liver oil· Ongoing

      It carries high preformed vitamin A, which is teratogenic at excess doses.

    4. 4

      Start in the second trimester· Weeks 12 onward

      This matches the trial protocols and the timing of fetal DHA accumulation.

    5. 5

      Continue through lactation· Postpartum

      Breast milk DHA reflects maternal intake.

    Not cod liver oil

    Cod liver oil contains high preformed vitamin A, which can harm a developing fetus. Use a purified fish oil or algal DHA product instead.

    Evidence

    The linked Cochrane systematic review pooled 19,927 women across trials of omega-3 addition during pregnancy. It found reduced preterm birth before 37 weeks and reduced early preterm birth, alongside a small increase in prolonged gestation.

    Cochrane systematic review linked to this pairing.

    Omega-3 fatty acid addition during pregnancy

    Score: 9/10
    2018
    systematic_review
    n=19927

    Middleton P, Gomersall JC, Gould JF +3 more

    Omega-3 supplementation reduced preterm birth before 37 weeks and early preterm birth

    View source
    Best available evidence
    Cochrane systematic review, n=19927
    Primary benefit
    Reduced preterm birth before 37 weeks and early preterm birth
    Trade-off
    Small increase in prolonged gestation
    Studied dose
    Commonly 500-1000 mg DHA daily from the second trimester
    Main limitation
    Trials vary in dose, form and start time

    Safety

    Purified omega-3 is considered safe in pregnancy and is routinely recommended in many maternity settings. The safety issues are about product choice and monitoring rather than the fatty acids.

    Cautions

    Avoid cod liver oil due to preformed vitamin A
    Use products tested for mercury and PCBs
    Small increase in prolonged gestation; keep obstetric monitoring
    Mild antiplatelet effect relevant near delivery
    Discuss with your maternity team before starting

    Interactions & Conflicts

    Interactions in pregnancy centre on bleeding around delivery and on avoiding excess vitamin A from the wrong product. Both are manageable with the right choices.
    Interacts withSeverityMechanismAction
    Anticoagulants in pregnancy
    high
    		Additive bleeding risk around deliveryOnly under obstetric and haematology supervision
    Cod liver oil or high-vitamin-A products
    high
    		Preformed vitamin A is teratogenic in excessAvoid entirely; use purified fish or algal oil
    Prenatal multivitamins containing DHA
    low
    		Doses add up across productsTotal your DHA before adding a separate product
    Aspirin prescribed for pre-eclampsia risk
    moderate
    		Additive antiplatelet effectConfirm the combination with your obstetric team

    References

    1. Middleton P et al. Omega-3 fatty acid addition during pregnancy. Cochrane Database Syst Rev. 2018

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.